On November 2, a 5,000 Ether (ETH) long position held by an investor named 黄立成 was valued at approximately $11.43 million, with an unrealized profit of about $110,000. The position uses 25 times leverage, meaning the exposure is 25 times the margin committed, which can greatly amplify gains or losses. The $110,000 gain is a paper profit on an open position and not realized until the trade is closed. This example illustrates the high-risk, high-reward nature of leveraged trading in the cryptocurrency market.
The Ether long position held by 黄立成 was valued at $11.43 million as of November 2, 2026. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Nov 02, 2026 18:41 WIB: out of 50 major cryptocurrencies priced on Pluang, 5 rose and 44 fell today. Notable movers include EOS at Rp12,649 (+8.13%) with a typical hold time of 87 days, COTI at Rp184 (-6.58%) with 89% buy order activity, and BAT at Rp2,394 (-5.78%) with 73% sell order activity.
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against Tigo Energy, Fluence Energy, and Anavex Life Sciences. The lawsuits allege these companies made false or misleading stat...
Heineken N.V. has repurchased a total of 9,510,681 shares under the second tranche of its €1.5 billion share buyback program, spending €679.2 million as of October 30, 2026. The company bought 159,700 shares on the exchange and 160,530 shares from He...
Alvotech, a global biotech company specializing in biosimilars, announced its management team will participate in several investor conferences in November 2026, including events in London, Oslo, and Stockholm. These presentations and fireside chats w...
Alvotech, a global biotech company specializing in biosimilar medicines, announced its management team will participate in several investor conferences throughout November 2026. These include events in London, Oslo, and Stockholm, featuring presentat...
Alvotech, a global biotechnology company specializing in biosimilar medicines, will participate in four international investor conferences in November held in the UK, Norway, and Sweden. These events include presentations and analyst discussions host...
